FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology and molecular biology. Disclosed are a universal inducible promoter, a vector and a host cell based thereon, as well as a method for producing said host cell. Inducible promoter includes binding sites of transcription factors STAT3, STAT5 and AP-1 and minimal promoter, wherein binding sites of transcription factors are located from 5' end to 3' end one after another in sequence STAT3-STAT5-AP-1.
EFFECT: proposed inventions enable to analyze activity of various target proteins.
15 cl, 17 dwg, 1 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PIGAS CELL LINE CONTAINING STAT-1 TRANSCRIPTION FACTOR BINDING SITE STABLE-INTEGRATED IN GENOME | 2015 |
|
RU2619643C1 |
| SELF-REGULATING APOPTOSIS OF INFLAMMATORY CELLS USING GENETIC THERAPY | 1998 |
|
RU2198683C2 |
| NUCLEIC ACID HAVING PROMOTER ACTIVITY AND ITS USE | 2022 |
|
RU2818112C2 |
| REGULATORY MOLECULES OF NUCLEIC ACIDS FOR ENHANCEMENT OF SEED-SPECIFIC AND/OR SEED-PREFERRED GENE EXPRESSION IN PLANTS | 2010 |
|
RU2559534C2 |
| REGULATORY NUCLEIC ACID MOLECULES FOR ENHANCING SEED-SPECIFIC AND/OR SEED-PREFERENTIAL GENE EXPRESSION IN PLANTS | 2010 |
|
RU2692924C2 |
| NUCLEOTIDE SEQUENCE ABLE TO INHIBIT IL-6 ACTIVITY, PLASMID VECTOR FOR TRANSFECTION INTO MAMMALIAN CELLS, NUCLEOTIDE SEQUENCE USED IN THERAPY, PHARMACEUTICAL COMPOSITION (VARIANTS) | 1995 |
|
RU2205874C2 |
| MULTIPURPOSE CANCER-SPECIFIC PROMOTERS AND USING THEM IN ANTI-CANCER THERAPY | 2013 |
|
RU2539764C2 |
| SYNTHETIC 5'UTR (UNTRANSLATED REGIONS) EXPRESSION VECTORS AND METHOD OF INCREASING TRANSGENIC EXPRESSION | 2008 |
|
RU2524431C2 |
| FLUORESCENT REPORTER SYSTEMS FOR ASSESSING EPITHELIAL AND/OR MESENCHYMAL CELL STATE | 2017 |
|
RU2705251C2 |
| THERAPEUTIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | 2015 |
|
RU2711147C2 |
